Vector-borne diseases (VBDs) represent a significant challenge to public health in India. The country's vast geographical diversity and climatic variations create an environment conducive to the spread of various vectors, leading to a high disease burden.
India is currently grappling with a multitude of VBDs including malaria, dengue, chikungunya, and Japanese encephalitis. Malaria alone accounts for a significant portion of the disease burden, with the World Health Organisation estimating around 6.7 million cases in 2018. Additionally, the increasing incidence of dengue and chikungunya pose a substantial threat to public health.
The fight against VBDs in India is fraught with challenges. These include the lack of effective vector control strategies, inadequate healthcare infrastructure, and gaps in disease surveillance. Additionally, the effects of climate change, urbanisation, and population mobility further exacerbate the situation.
Effective control of VBDs necessitates a multi-pronged approach. This includes strengthening surveillance systems, improving diagnostic capabilities, and implementing effective vector control strategies. In addition, increasing community awareness and participation, and fostering intersectoral coordination are crucial. The recent launch of the National Vector Borne Disease Control Programme (NVBDCP) is a step in the right direction, aiming to reduce the morbidity and mortality associated with VBDs.
Vector-borne diseases pose a significant public health challenge in India. While the situation is daunting, a concerted effort involving the government, healthcare professionals, and the community can make a significant difference. By strengthening healthcare infrastructure, improving surveillance, and implementing effective control strategies, India can turn the tide against these diseases. The battle is far from over, but with a comprehensive and coordinated approach, victory is within reach.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation